Ironwood Pharmaceuticals, Inc.
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:founded |
1998
|
| gptkbp:founder |
gptkb:Gregory_P._Barrett
gptkb:Mark_Currie gptkb:Peter_Hecht gptkb:Thomas_A._Giordano |
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ironwood Pharmaceuticals, Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Mark_Currie
gptkb:Thomas_McCourt |
| gptkbp:notableProduct |
gptkb:LINZESS
|
| gptkbp:numberOfEmployees |
~300 (2023)
|
| gptkbp:product |
gptkb:linaclotide
IBS-C treatments |
| gptkbp:publiclyTraded |
true
|
| gptkbp:servesArea |
gptkb:United_States
|
| gptkbp:specializesIn |
gastrointestinal diseases
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:IRWD
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.ironwoodpharma.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_IRWD
|
| gptkbp:bfsLayer |
6
|